XFOR(X4 Pharmaceuticals, Inc.) · 财务报表

XFOR(X4 Pharmaceuticals, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$0$0$0$2.60M$35.11M
毛利润—$0$0$1.80M$29.36M
营业利润−$85.11M−$87.57M−$107.52M−$36.40M−$86.88M
净利润−$88.70M−$93.87M−$101.17M−$37.45M−$79.20M
经营现金流−$70.91M−$77.10M−$96.51M−$130.90M−$85.62M
自由现金流−$71.52M−$77.20M−$96.57M−$131.23M−$85.62M
摊薄每股收益$-119.70$-45.60$-17.07$-5.59$-1.87

X4 Pharmaceuticals, Inc. XFOR